Aim
To identify SMI characteristics associated with meeting CVD treatment and prevention guidelines.
Design and setting
Population-based electronic health record database linkage between primary care and the sole provider of secondary mental health care services in south east London, UK.
Method
Cardiovascular disease prevalence, risk factor recording, and Quality and Outcomes Framework (QOF) clinical target achievement were compared among 4056 primary care patients with SMI whose records were linked to secondary healthcare records and 270 669 patients without SMI who were not known to secondary care psychiatric services, using multivariate logistic regression modelling. Data available from secondary care records were then used to identify SMI characteristics associated with QOF clinical target achievement.
Results
Patients with SMI and with coronary heart disease and heart failure experienced reduced prescribing of beta blockers and angiotensinconverting enzyme inhibitor/angiotensin receptor blockers (ACEI/ARB). A diagnosis of schizophrenia, being identified with any indicator of risk or illness severity, and being prescribed with depot injectable antipsychotic medication was associated with the lowest likelihood of prescribing.
provides a safe haven environment with strict governance arrangements. Data were linked using encrypted NHS numbers, which were subsequently removed and destroyed, fully anonymising the linked dataset.
Measures
Lambeth DataNet (LDN). Data were extracted on sex, year of birth, ethnic group, and 2011-defined lower super output area (LSOA). LSOA data were used to estimate deprivation on the basis of patient area of residence using the Index of Multiple Deprivation (IMD-2010) and a conversion to 2011 LSOA values. GP clinical register data (lists established and maintained by practices of patients identified with particular clinical outcomes for QOF purposes) were collected for heart failure (HF), coronary heart disease (CHD), hypertension (HYP), and stroke/transient ischaemic attack (STIA). Data were also collected on CVD risk factor recording, for example BP; clinical values and dates; and, mean number of primary care consultations (including GP, nurse, face-to-face, and telephone) between 2010 and 2013. A binary variable was created to distinguish median or below and above median annual number of consultations.
Case Register Interactive Search (CRIS). Diagnostic codes for any primary or secondary diagnosis of schizophrenia, bipolar affective disorder, and schizoaffective disorder or other non-organic psychoses were extracted. An indicator of SMI severity was created, coding patients with SMI as 1 if they ever had a record of: an inpatient stay, being treated under the Mental Health Act, difficulty managing their physical health, or contact with Assertive Outreach, Crisis or A&E liaison team (or 0 if they had not been recorded with any of these). Similarly, an indicator of risk coded patients with SMI as 1 or 0 to indicate if they had ever been identified under the 'violence and aggression' subscale of risk assessment with a history of violence, non-compliance, or forensic history. Lastly, binary indicators of antipsychotic medication prescription were extracted; including binary indicators of atypical, typical, and depot injectable medication.
Statistical analyses
Pearson's χ 2 tests and logistic regression analyses were used to compare CVD prevalence, risk factor recording, QOF target achievement, and primary care consultation frequency by SMI status. Using
How this fits in
Patients with severe mental illness (SMI) experience lower life expectancy than the general population. Suboptimal treatment of cardiovascular diseases has been identified as a potential contributory factor. This study found that patients with SMI in south east London are underprescribed beta blockers and angiotensin converting enzyme inhibitors/angiotensin receptor blockers as secondary prevention after coronary heart disease and heart failure. This may help clinicians to identify patients at greatest risk of suboptimal treatment. 
Sociodemographic characteristics of SMI subgroups
The SMI characteristics extracted from secondary care data are shown in Table 2 .
Adjusting for all sociodemographic characteristics simultaneously (data not shown), being black African, black Caribbean, other black, and of a younger age were associated with indicators of risk and severity, and with receiving depot injectable antipsychotic medication; male sex was also associated with risk. Being black Caribbean and older was associated with receipt of typical antipsychotics, whereas younger age and being black African was associated with receipt of atypical antipsychotics. Relative to those with a diagnosis of schizophrenia, those diagnosed with bipolar disorder were younger, more likely to be identified as British/mixed British, female, and to consult primary care more frequently (P = 0.01).
Those diagnosed with schizoaffective disorder/other non-organic psychoses were younger, more likely to be female, and to consult primary care less frequently relative to patients with schizophrenia (except where indicated, all P-values <0.001).
CVD risk factor recording and QOF target achievement CVD risk factor recording (for example BP) was, in general, high for patients with and without SMI ( 
Regression analyses of QOF target achievement
Regression analyses (Table 4 ) focused on differences in CVD prescribing by SMI status as these differences have previously been identified as a potential contributor to excess cardiovascular mortality among patients with SMI, 12 and were the key differences identified in Table 3 . Associations between SMI status and beta blocker and ACEI/ARB medication among patients with HF remained after accounting for both sociodemographic characteristics and consultation rates. Among patients with CHD, the association between SMI status and beta blocker prescription was accounted for by ethnic group but the shortfall in ACEI/ARB prescribing among CHD patients with SMI remained after adjustments. For analyses examining SMI-subgroups associated with beta blocker and ACEI/ ARB prescribing, CHD and HF were combined because of small numbers (Table  5) . After adjustments, prescribing of beta blocker and ACEI/ARB medication among patients with CHD or HF combined was significantly lower for patients with SMI overall (OR 0.48 and 0.42, respectively); and was particularly reduced for patients ever prescribed depot injectable antipsychotic medication (OR 0.22 and 0.32, respectively), those with any indicator of risk (OR 0.25 and 0.22, respectively), those diagnosed with schizophrenia (OR 0.38 and 0.27, respectively), and those with any indicator of SMI severity (OR 0.39 and 0.31, respectively).
DISCUSSION

Summary
Elevated rates of CVDs were found among patients with SMI; however, there may be underrecording of CVD comorbidities among patients with SMI and with established CVDs. Risk factor recording was high, although significant differences by SMI status were identified. Overall, QOF target achievement was not impaired in patients with SMI but significant consistent associations were found between SMI status and reduced prescribing of ACEI/ARB and beta blocker medication as secondary prevention of CHD and HF. Patients with SMI and with schizophrenia, those identified with any indicator of risk or illness severity, and those ever prescribed depot injectable antipsychotics were least likely to be prescribed ACEI/ARBs and beta blockers.
Strengths and limitations
This study makes use of a population-based data linkage between primary and secondary care records. It was possible to identify patient and illness-related characteristics associated with recording and treatment of CVDs and to highlight issues warranting further investigation that may best target disparities and reduce inequalities in physical comorbidity and mortality.
The main limitation pertains to the generalisability to other geographical areas; however, the present findings are in line with evidence from national and international research, and it is believed that this study is proof of principle of the utility of data linkage, which could be used elsewhere to corroborate the findings. Although the analyses focus on incentivised QOF targets, it is possible that discrepancies in non-QOF targets may differ.
Comparison with existing literature
Although patients with SMI were more likely to be recorded with CVDs overall, little evidence was found for elevated rates of CVD comorbid conditions among those with established CVDs. Previous research has found no difference in the pattern of physical health co-and multimorbidities by SMI status and lower than expected rates of certain CVDs among patients with SMI given higher CVD-related mortality. 3, 19, 20, 21 One of several explanations suggested is that this may be linked to less frequent GP consultations 20, 21 ; however, in this study, elevated consultation rates are reported among patients with SMI overall, and among patients with SMI and with established CVD, in line with previous findings. 22 Patients with SMI were less likely to have a CVD risk assessment, and although such tools may not be as accurate for the SMI population, 23, 24 it is unclear whether this concern or other factors accounted for this observation.
Lower than expected differences were found in the proportion of black Caribbean patients with SMI among those with CHD and STIA. This suggests that either SMI status does not confer an excess risk of these outcomes or that CHD and STIA is less frequently recorded among black Caribbean patients with SMI; for example, because of excess mortality. In line with previous findings, 7, 14, 21, 25 this study found evidence for reduced prescription of ACEI/ ARB and beta blocker medications for CVD secondary prevention. Underprescribing in CVDs has been linked previously with excess mortality among patients with SMI 7, 12, 21, 25, 26 and therefore may contribute to disparities in life expectancies. Reduced ACEI/ARB prescribing in CHD among patients with SMI could partly reflect differences in the effectiveness of these drugs as hypotensive agents among black Caribbean and black African patients. 27 National Institute for Health and Care Excellence (NICE) HYP guidelines 28 indicate prescribing of ARBs rather than ACEIs among black patients; however, the associations remained after adjustments for ethnic group and were robust when ACEI and ARB prescriptions were analysed separately. Reduced prescribing is also unlikely to be linked to reduced attendance at primary care as greater consultation frequency was found among patients with SMI, and adjustments strengthened negative associations with prescribing.
There may, however, be reluctance to prescribe certain CVD medications because of concerns about adherence. Adherence may be lower for drugs where the dose has to be up-titrated to maximally tolerated doses as for beta blockers and ACEI/ARBs; these medications require monitoring, and thus adherence to a monitoring regimen to assess for side-effects. Monitoring also involves regular blood tests; such a commitment may be perceived as too demanding for GPs assessing patients with SMI, and/or patients with SMI may be less willing to commit themselves to such monitoring. However, a recent US study assessing adherence in patients with and without schizophrenia found no evidence for reduced adherence to ACEI/ ARB medication. 29 One reason previously suggested for reluctance to prescribe certain cardiovascular medications is the potential for harm in overdose.
14,21 Although research does not support an association between cardiovascular medication and excess suicide, 30, 31 practitioners could conceivably have concerns around correct adherence among patients with SMI, for example, leading to accidental overdose.
Further quantitative and qualitative work may usefully further explore these explanations. Qualitative evidence suggests that primary care physicians may view patients with SMI as harder to manage, 31, 32 and be less willing to intervene when cardiovascular risk factors are identified. 33 Further, there may be reluctance among patients with SMI to accept prescriptions because of mistrust or lack of adequate communication between physician and patient. 34 For patients with greater illness severity, the role of secondary care physicians may be more pertinent in managing physical health.
Lastly, QOF exception rates (for example, because of informed dissent or treatment unsuitability) are higher in patients with SMI, 35, 36 potentially inflating QOF achievement. The present analyses did not exclude exception reported patients, however, so the reported achievement rates were not influenced by exception reporting among patients with SMI.
Beta blocker and ACEI/ARB prescription was reduced in patients with SMI with CHD or HF overall, but the reduction was greatest in patients with SMI identified with any indicator of risk, prescription of depot injectable antipsychotics, schizophrenia diagnosis, and any indicator of SMI severity. To the authors' knowledge, these associations have not been previously investigated; however, Laursen et al 25 reported that rates of 'unnatural' deaths were elevated among patients with SMI who were not prescribed cardiovascular medication, also indicating an association with illness severity. The subgroups identified as most at risk of underprescribing may be those most likely to be seen as the 'hardest to treat' by GPs and those least likely to commit to the monitoring and follow-up as implied before. Further qualitative work should explore these associations among clinicians and patients who have been identified as at risk of underprescribing.
Implications for practice
These findings deepen the understanding of disparities in morbidity and health care among individuals with SMI and help to build possible explanations for these discrepancies by identifying characteristics of patients with SMI associated with the lowest likelihood of optimal treatment. The results underline the value of closer working between primary and secondary care in improving outcomes for patients with SMI.
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